MSD recruit Taiho and Astex to assist in developing KRAS therapies

MSD announces worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals, both subsidiaries of Otsuka, to develop small molecule inhibitors against several drug targets. It was revealed that the partnership intends to investigate drugs including the KRAS oncogene, which are currently being investigated for the treatment of cancer. KRAS is among the

Continue Reading

GSK and Lyell to collaborate on cancer cell therapies

GSK and Lyell Immunopharma have announced a five-year collaboration to develop new technologies with the aim of improving cell therapies for cancer patients. In the announcement the companies explained that the collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including GSK3377794, which targets the NY-ESO-1 antigen that is expressed across multiple

Continue Reading

Birmingham Scientist find new research could boost immunotherapy treatments

Cancer Research UK announces scientists have discovered a method to demolish the protective wall that surrounds tumours, potentially re-exposing them to the killing power of the immune system and immunotherapy treatments. A study (published in EBioMedicine) found that the new approach could help to boost the effects of innovative cancer treatments, such as CAR-T therapy, which so

Continue Reading

Scientist at UK’s first convergent science centre looking to use microbubbles to destroy cancer

As part of the new £13 million Cancer Research UK Convergence Science Centre at The Institute of Cancer Research, scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles” Cancer Research UK has announced the development of the new treatment that doesn’t require invasive surgery, in

Continue Reading